RIGL
Strong BuyFull HouseAI screen passRigel Pharmaceuticals, Inc. · Healthcare · United States · $899M cap · $11.5M/day traded
$50.55 +1.3% · close 27 Oct · scored 28 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
Report expected 3 Nov: the next-year EPS estimate has risen 3.3% over the last 14 weeks.
As of 28 Oct 2026, MoatMap's StockRank for Rigel Pharmaceuticals, Inc. (RIGL) is 98/100, ranked against 24,000+ stocks in 35 markets (Quality 81, Value 69, Momentum 65, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Rigel Pharmaceuticals demonstrates robust financial quality and sustained operating momentum across its commercial-stage hematology and oncology portfolio. The company is executing an active share repurchase program, and recent commercial commercialization milestones for targeted oncology therapies support ongoing cash generation without any negative revision pressure.
ABOUT RIGEL PHARMACEUTICALS, INC.
Read
Rigel Pharmaceuticals, Inc. is a commercial-stage biotechnology company dedicated to the discovery, development, and provision of novel small molecule drugs for serious diseases. Its approved product, TAVALISSE, is used to treat chronic immune thrombocytopenia, showcasing its expertise in immunology. Rigel maintains a competitive edge through its proprietary R&D platform and pipeline targeting various immunological and oncological conditions.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 120.2M | 116.9M | 179.3M | 294.3M | 34.8% | 276.8M | 305.7M | 372.8M | 12.6% |
| EPS | -3.40 | -1.44 | 0.99 | 20.40 | 1960.6% | 16.88 | 11.24 | 15.67 | -12.4% |
| Shares | 17.3M | 17.5M | 17.7M | 18.3M | +5.6% | 18.7M | — | — | — |
| Debt | 41.6M | 60.6M | 60.0M | 53.3M | 8.7% | 40.0M | — | — | — |
| Equity | -13.6M | -28.6M | 3.3M | 391.5M | 11806.3% | — | — | — | — |
| Op CF | -73.8M | -5.7M | 31.5M | 75.7M | 140.4% | 79.4M | — | — | — |
| Inv CF | 72.8M | -4.3M | 4.1M | -92.4M | — | — | — | — | — |
| Fin CF | 6.5M | 18.4M | -11.6M | 0.6M | — | — | — | — | — |
Above its 200-day average and 3% below its 52-week high.
Swung more than 77% of stocks we rank over the past year (63% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RIGL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RIGL | Rigel Pharmaceuticals, Inc.(you) | $899M | 98 | Strong Buy |
| CRMD | CorMedix Inc. | $612M | 98 | Strong Buy |
| PBYI | Puma Biotechnology, Inc. | $569M | 97 | Strong Buy |
| ZVRA | Zevra Therapeutics, Inc. | $583M | 91 | Strong Buy |
| INVA | Innoviva, Inc. | $1.5B | 92 | Strong Buy |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.1B | 100 | Strong Buy |
| 1521.HK | Frontage Holdings Corporation | $387M | 94 | Strong Buy |
| ABUS | Arbutus Biopharma Corporation | $644M | 83 | Strong Buy |
| NRIX | Nurix Therapeutics, Inc. | $2.8B | 95 | Strong Buy |
| PLX | Protalix BioTherapeutics, Inc. | $205M | 98 | Strong Buy |
Peer medians: ROE -30.5% · P/E 27.3x · Gross margin 63.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.